Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00108758
Status:
COMPLETED
Last Update Posted:
2017-01-12
First Post:
2005-04-18
Brief Title:
Efficacy of NovoSeven in Bleeding Prophylaxis in Hemophilia
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
Exploratory Multi-centre Randomised Double-blind Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII rFVIIaNovoSeven in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is conducted in Africa Asia Europe South America and the United States of America USA
The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven in haemophilia A and B patients with inhibitors
The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven in haemophilia A and B patients with inhibitors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None